QMS Medical Allied Services Limited (NSE:QMSMEDI)
148.39
+7.06 (5.00%)
Aug 21, 2026, 1:35 PM IST
NSE:QMSMEDI Revenue
QMS Medical Allied Services had revenue of 572.84M INR in the quarter ending June 30, 2026, with 23.21% growth. This brings the company's revenue in the last twelve months to 1.83B, up 6.51% year-over-year. In the fiscal year ending March 31, 2026, QMS Medical Allied Services had annual revenue of 1.73B with 10.81% growth.
Revenue (ttm)
1.83B
Revenue Growth
+6.51%
P/S Ratio
1.45
Revenue / Employee
20.59M
Employees
89
Market Cap
2.65B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.73B | 168.62M | 10.81% |
| Mar 31, 2025 | 1.56B | 338.86M | 27.75% |
| Mar 31, 2024 | 1.22B | 180.85M | 17.38% |
| Mar 31, 2023 | 1.04B | -422.80M | -28.90% |
| Mar 31, 2022 | 1.46B | 242.89M | 19.90% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 599.11B |
| Cipla | 280.68B |
| Apollo Hospitals Enterprise | 264.30B |
| Divi's Laboratories | 112.30B |
| Infinium Pharmachem | 1.90B |
| Nureca | 1.53B |
| Lyka Labs | 1.34B |
| TAKE LIMITED | 845.59M |